GlassScriptPhysician profile
James G Cruse
NPI 1376507517
$8,276.47
in general payments reported to CMS, 2019-2025
54 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $701 · 2021: $1,132 · 2022: $1,071 · 2023: $1,388 · 2024: $1,401 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,427.39 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,095.65 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,070.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $791.67 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $776.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $717.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $547.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $487.77 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.40 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.11 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $177.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $172.73 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Tandem Diabetes Care, INC. | $168.71 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| E.R. Squibb & Sons, L.L.C. | $139.75 | 2019-2023 | Eliquis |
| Daiichi Sankyo INC. | $134.33 | 2019-2022 | |
| Astellas Pharma US INC | $105.50 | 2019-2023 | Veozah |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cruse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.